7348664
Descripción
Fichas por Shane Naki, actualizado hace más de 1 año
|
Creado por Shane Naki
hace casi 8 años
|
|
| Pregunta | Respuesta |
| What is CRISPR | clustered regulatory interspaced palindromic short repeats gene editing to directly modify disease related changes in genome |
| What is CAGR | compound annual growth rate measure of growth over multiple time periods; growth rate from the initial investment value to the ending investment value if you assume that the investment has been compounding over the time period. |
| CAGR for US through 2021 | 4-7% |
| What is the reduction in overall spending over the next five years | $143.5 billion |
| how does this compare to previous 5 years | 1.5 times the impace as in the past five years |
| What major contributors cause this impact | loss of exclusivity and introduction of biosimilars |
| Pricing and Growth in Europe | Pricing and Growth in Europe |
| What are the EU5 | France Italy Germany Spain United Kingdom |
| What is BREXIT | British exit from the European Union (2016) |
| How does BREXIT affect on the UK pharmaceutical market | modestly: 1.5 % slower growth rate in the downside scenario |
| BY THE NUMBERS | BY THE NUMBERS |
| Transformations in Disease Treatments | Transformations in Disease Treatments |
| evolution of new platforms | CRISPR harnessing power of gut microbiome regenerative cell tech |
| what are the immune checkpoint inhibitors that will most contribute to growth of the market in the next 5 years | CTLA4 PD1 inhibitors (nivolumab and pembrolizumab) |
| What combination drugs are being tried for NSCLC | anti PDL1 atezolizumab (Tecentriq) + nivolumab (Opdivo) + platinum based doublet chemotherapy PD1 combination pemetrexed, pembrolizumab (Keytruda), and carboplatin |
| Trends in US medicines | Trends in US medicines |
| How do UK and germany control growth in their pharma market | limit sales of new medicines and trigger negotiations to avoid the unexpected budet busters of the last two years |
| How does France control growth in their pharma market | seek lower prices, greater generic usage, and additional reforms to the payback system where manufacturers repay the government if drug spend exceeds set levels |
| How does italy control growth in their pharma market | shifting spending to the hospital sector where government budgeting has greater direct control |
| How does spain control growth in their pharma market | devolved regional budgeting |
| impact on growth from brexit | 1.5% slower growth |
| why does controlling healthcare spending in pharma matter | intend to balance desirable medical progress with a nation's ability to pay on a sustainable basis |
¿Quieres crear tus propias Fichas gratiscon GoConqr? Más información.